We are live on ! Find out more
AVTX icon

Avalo Therapeutics

55 hedge funds and large institutions have $127M invested in Avalo Therapeutics in 2020 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 19 increasing their positions, 12 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 4

58% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 12

43% more capital invested

Capital invested by funds: $88.5M → $127M (+$38.5M)

28% more funds holding

Funds holding: 4355 (+12)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more ownership

Funds ownership: 0.02%0.02% (+0%)

Holders
55
Holders Change
+12
Holders Change %
+27.91%
% of All Funds
1.13%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
16
Increased
19
Reduced
12
Closed
4
Calls
Puts
Net Calls
Net Calls Change

AVTX Hedge Fund Activity: Q2 2020 in Review

55 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q2 2020, worth a combined $127M — up 43% from $88.5M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new AVTX positions and 4 closed out — a net gain of 12 holders — while 19 added to existing stakes and 12 trimmed.

The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $14.3M. The largest seller was Ikarian Capital, cutting an estimated $407K.

  • 55 institutional investors held Avalo Therapeutics (AVTX) as of Q2 2020, up from 43 in Q1 2020.
  • Funds reported $127M of Avalo Therapeutics stock for Q2 2020, up 43% quarter-over-quarter.
  • 16 funds opened new Avalo Therapeutics positions in Q2 2020 and 4 closed out, a net change of +12 holders.
  • The largest Avalo Therapeutics buyer in Q2 2020 was Nantahala Capital Management, an estimated $14.3M added.
  • The largest Avalo Therapeutics seller in Q2 2020 was Ikarian Capital, an estimated $407K sold.

Based on aggregated 13F filings for Q2 2020.